drugset
drugset / Trial / NCT06523595

Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults

NCT06523595 ↗

Phase 1 Completed 31 enrolled Vertex Pharmaceuticals Incorporated
NaCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic drug-drug interactions, safety, and tolerability of co-administration of VX-993 and metformin in healthy participants.

Timeline

Start
2024-07-31
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule — Oral
Subject VX-993 Unknown — Oral

Indications

No indication recorded.